![Sutro Biopharma Inc](/common/images/company/N_STRO.png)
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated ce... Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Show more
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.47 | -10.2396514161 | 4.59 | 4.78 | 3.99 | 497167 | 4.36427975 | CS |
4 | 0.89 | 27.5541795666 | 3.23 | 5.17 | 3.04 | 627946 | 4.32415766 | CS |
12 | 0.35 | 9.28381962865 | 3.77 | 5.17 | 2.75 | 722903 | 3.74949848 | CS |
26 | -0.45 | -9.84682713348 | 4.57 | 6.13 | 2.75 | 865539 | 4.13430339 | CS |
52 | -0.28 | -6.36363636364 | 4.4 | 6.13 | 2.005 | 804042 | 3.92834775 | CS |
156 | -17.475 | -80.9215096087 | 21.595 | 23.7 | 2.005 | 602888 | 5.81730462 | CS |
260 | -4.68 | -53.1818181818 | 8.8 | 28.3 | 2.005 | 472644 | 8.70765455 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.